Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DGX Quest Diagnostics	$178.85 +1.3%	$176.47	$136.99 ▼ $182.38	$19.97B	0.49	987,685 shs	436,517 shs
EXAS Exact Sciences	$52.82 -1.9%	$53.73	$39.97 ▼ $72.83	$9.96B	0.95	2.57 million shs	1.67 million shs
MYGN Myriad Genetics	$5.60 -0.5%	$5.09	$3.81 ▼ $29.30	$516.21M	1.91	1.26 million shs	463,756 shs
NTRA Natera	$161.50 0.0%	$160.34	$92.14 ▼ $183.00	$22.05B	1.73	1.42 million shs	468,868 shs

A Beginner's Guide to Investing in Cannabis

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DGX Quest Diagnostics	0.00%	+0.63%	+2.51%	+8.71%	+27.34%
EXAS Exact Sciences	0.00%	-1.56%	-3.75%	+20.50%	+18.50%
MYGN Myriad Genetics	0.00%	+6.67%	+10.02%	-30.61%	-77.51%
NTRA Natera	0.00%	-3.85%	-1.38%	+16.81%	+43.25%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DGX Quest Diagnostics	4.9386 of 5 stars	2.3	4.0	4.2	4.7	2.9	2.5	2.5
EXAS Exact Sciences	4.9409 of 5 stars	4.5	5.0	0.0	4.7	3.4	2.5	0.6
MYGN Myriad Genetics	4.1562 of 5 stars	4.1	3.0	0.0	4.1	0.0	1.7	0.6
NTRA Natera	2.1396 of 5 stars	2.5	2.0	0.0	0.0	3.4	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DGX Quest Diagnostics	2.69	Moderate Buy	$185.73	3.85% Upside
EXAS Exact Sciences	2.95	Moderate Buy	$70.40	33.30% Upside
MYGN Myriad Genetics	2.13	Hold	$14.38	156.87% Upside
NTRA Natera	3.00	Buy	$184.63	14.32% Upside

Current Analyst Ratings Breakdown

Latest MYGN, DGX, EXAS, and NTRA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/24/2025	EXAS Exact Sciences	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$75.00 ➝ $65.00
5/21/2025	MYGN Myriad Genetics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Sector Outperform ➝ Sector Perform	$20.00 ➝ $6.00
5/15/2025	MYGN Myriad Genetics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$12.50 ➝ $9.00
5/15/2025	NTRA Natera	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$205.00 ➝ $210.00
5/9/2025	NTRA Natera	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$211.00 ➝ $218.00
5/9/2025	NTRA Natera	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$160.00 ➝ $190.00
5/8/2025	MYGN Myriad Genetics	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Peer Perform
5/7/2025	MYGN Myriad Genetics	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$18.00
5/7/2025	MYGN Myriad Genetics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$14.00 ➝ $8.00
5/7/2025	MYGN Myriad Genetics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$19.00 ➝ $10.00
5/7/2025	MYGN Myriad Genetics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$16.00 ➝ $7.00

(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DGX Quest Diagnostics	$9.87B	2.02	$13.65 per share	13.10	$61.38 per share	2.91
EXAS Exact Sciences	$2.76B	3.61	$5.57 per share	9.48	$12.98 per share	4.07
MYGN Myriad Genetics	$837.60M	0.62	$1.00 per share	5.60	$7.70 per share	0.73
NTRA Natera	$1.70B	13.00	N/A	N/A	$9.05 per share	17.85

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DGX Quest Diagnostics	$871M	$7.91	22.61	17.05	2.47	8.81%	15.11%	6.65%	7/22/2025 (Estimated)
EXAS Exact Sciences	-$1.03B	-$5.51	N/A	105.63	11.39	-36.06%	-3.75%	-1.68%	7/30/2025 (Estimated)
MYGN Myriad Genetics	-$127.30M	-$1.12	N/A	N/A	N/A	-12.20%	-4.95%	-3.39%	8/5/2025 (Estimated)
NTRA Natera	-$190.43M	-$1.47	N/A	N/A	N/A	-10.36%	-18.29%	-11.68%	8/14/2025 (Estimated)

Latest MYGN, DGX, EXAS, and NTRA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/30/2025	Q2 2025	EXAS Exact Sciences	-$0.04	N/A	N/A	N/A	$774.43 million	N/A
7/22/2025	Q2 2025	DGX Quest Diagnostics	$2.56	N/A	N/A	N/A	$2.73 billion	N/A
5/8/2025	Q1 2025	NTRA Natera	-$0.59	-$0.50	+$0.09	-$0.50	$446.68 million	$501.83 million
5/6/2025	Q1 2025	MYGN Myriad Genetics	-$0.05	-$0.03	+$0.02	N/A	$200.37 million	$195.90 million
5/1/2025	Q1 2025	EXAS Exact Sciences	-$0.37	-$0.21	+$0.16	-$0.54	$688.58 million	$706.79 million
4/22/2025	Q1 2025	DGX Quest Diagnostics	$2.15	$2.21	+$0.06	$1.94	$2.63 billion	$2.65 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DGX Quest Diagnostics	$3.20	1.79%	N/A	40.46%	14 Years
EXAS Exact Sciences	N/A	N/A	N/A	N/A	N/A
MYGN Myriad Genetics	N/A	N/A	N/A	N/A	N/A
NTRA Natera	N/A	N/A	N/A	N/A	N/A

Latest MYGN, DGX, EXAS, and NTRA Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/14/2025	DGX Quest Diagnostics	quarterly	$0.80	1.86%	7/7/2025	7/7/2025	7/21/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DGX Quest Diagnostics	0.84	1.44	1.31
EXAS Exact Sciences	0.97	2.73	2.38
MYGN Myriad Genetics	0.08	1.90	1.71
NTRA Natera	N/A	3.87	3.74

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DGX Quest Diagnostics	88.06%
EXAS Exact Sciences	88.82%
MYGN Myriad Genetics	99.02%
NTRA Natera	99.90%

Insider Ownership

Company	Insider Ownership
DGX Quest Diagnostics	8.16%
EXAS Exact Sciences	1.20%
MYGN Myriad Genetics	2.10%
NTRA Natera	7.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DGX Quest Diagnostics	56,000	111.64 million	102.53 million	Optionable
EXAS Exact Sciences	7,000	188.64 million	186.37 million	Optionable
MYGN Myriad Genetics	2,700	92.18 million	90.24 million	Optionable
NTRA Natera	4,434	136.55 million	126.17 million	Optionable

MYGN, DGX, EXAS, and NTRA Headlines

Recent News About These Companies

Natera, Inc. (NASDAQ:NTRA) Stock Holdings Increased by Calamos Advisors LLC

July 6 at 5:34 AM | marketbeat.com

Principal Financial Group Inc. Sells 91,190 Shares of Natera, Inc. (NASDAQ:NTRA)

July 5 at 5:30 AM | marketbeat.com

Sumitomo Mitsui DS Asset Management Company Ltd Makes New Investment in Natera, Inc. (NASDAQ:NTRA)

July 5 at 4:37 AM | marketbeat.com

Should You Invest in Natera (NTRA)?

July 4 at 5:27 PM | msn.com

Natera, Inc. (NASDAQ:NTRA) Insider Sells $500,310.00 in Stock

July 4 at 7:48 AM | insidertrades.com

Natera, Inc. (NASDAQ:NTRA) Shares Sold by KBC Group NV

July 4 at 4:07 AM | marketbeat.com

Solomon Moshkevich Sells 3,000 Shares of Natera, Inc. (NASDAQ:NTRA) Stock

July 3, 2025 | marketbeat.com

Insider Selling: Natera, Inc. (NASDAQ:NTRA) Director Sells 4,299 Shares of Stock

July 3, 2025 | marketbeat.com

Insider Selling: Natera, Inc. (NASDAQ:NTRA) CEO Sells 5,343 Shares of Stock

July 3, 2025 | marketbeat.com

1 Growth Stock with Exciting Potential and 2 to Be Wary Of

July 3, 2025 | msn.com

Robeco Institutional Asset Management B.V. Purchases Shares of 11,600 Natera, Inc. (NASDAQ:NTRA)

July 2, 2025 | marketbeat.com

Natera to Present Clinical and Economic Utility of Signatera at ESMO GI, Highlights Innovations in MRD

July 1, 2025 | businesswire.com

Mirae Asset Global Investments Co. Ltd. Has $8.07 Million Position in Natera, Inc. (NASDAQ:NTRA)

July 1, 2025 | marketbeat.com

Q1 Immuno-Oncology Earnings Review: First Prize Goes to Natera (NASDAQ:NTRA)

June 30, 2025 | msn.com

K.J. Harrison & Partners Inc Acquires 4,000 Shares of Natera, Inc. (NASDAQ:NTRA)

June 29, 2025 | marketbeat.com

Sumitomo Mitsui Trust Group Inc. Boosts Holdings in Natera, Inc. (NASDAQ:NTRA)

June 29, 2025 | marketbeat.com

Natera, Inc. (NASDAQ:NTRA) Shares Sold by Allspring Global Investments Holdings LLC

June 29, 2025 | marketbeat.com

Asset Management One Co. Ltd. Acquires New Shares in Natera, Inc. (NASDAQ:NTRA)

June 29, 2025 | marketbeat.com

Colonial River Investments LLC Invests $441,000 in Natera, Inc. (NASDAQ:NTRA)

June 28, 2025 | marketbeat.com

Jag Capital Management LLC Raises Stake in Natera, Inc. (NASDAQ:NTRA)

June 28, 2025 | marketbeat.com

Artemis Investment Management LLP Boosts Stake in Natera, Inc. (NASDAQ:NTRA)

June 27, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Uber and Tesla Surge on Robotaxis, Analyst Touts Texas Rides
By Leo Miller | June 25, 2025
View Uber and Tesla Surge on Robotaxis, Analyst Touts Texas Rides
Texas Instruments Stock: Congress Likes It, Should You Too?
By Thomas Hughes | June 24, 2025
View Texas Instruments Stock: Congress Likes It, Should You Too?

MYGN, DGX, EXAS, and NTRA Company Descriptions

Quest Diagnostics NYSE:DGX

$178.85 +2.25 (+1.27%)

Closing price 07/3/2025 03:56 PM Eastern

Extended Trading

$176.81 -2.04 (-1.14%)

As of 08:43 AM Eastern

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.

Exact Sciences NASDAQ:EXAS

$52.82 -1.05 (-1.94%)

Closing price 07/3/2025 03:12 PM Eastern

Extended Trading

$52.82 +0.01 (+0.01%)

As of 08:42 AM Eastern

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

Myriad Genetics NASDAQ:MYGN

$5.60 -0.03 (-0.53%)

Closing price 07/3/2025 02:38 PM Eastern

Extended Trading

$5.60 0.00 (0.00%)

As of 08:41 AM Eastern

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.

Natera NASDAQ:NTRA

$161.50 -0.07 (-0.04%)

Closing price 07/3/2025 03:54 PM Eastern

Extended Trading

$160.50 -1.00 (-0.62%)

As of 08:37 AM Eastern

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time